SRPT vs RARE

For growth investors, Sarepta Therapeutics, Inc.

(SRPT) is the stronger pick with 53. 0% revenue growth year-over-year, versus 20. 1% for Ultragenyx Pharmaceutical Inc. (RARE). Sarepta Therapeutics, Inc. (SRPT) offers the better valuation at 9. 3x trailing P/E (7. 3x forward), making it the more compelling value choice. Analysts rate Sarepta Therapeutics, Inc. (SRPT) a "Buy" — based on 54 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Sarepta Therapeutics, Inc.

(SRPT) delivered a total return of -70. 1%, compared to -76. 4% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: SRPT returned +30. 0% versus RARE's -60. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Ultragenyx Pharmaceutical Inc.

(RARE) is the lower-risk stock at 1. 42β versus Sarepta Therapeutics, Inc. 's 2. 02β — meaning SRPT is approximately 43% more volatile than RARE relative to the S&P 500.

By revenue growth (latest reported year), Sarepta Therapeutics, Inc.

(SRPT) is pulling ahead at 53. 0% versus 20. 1% for Ultragenyx Pharmaceutical Inc. (RARE). On earnings-per-share growth, the picture is similar: Sarepta Therapeutics, Inc. grew EPS 140. 3% year-over-year, compared to 7. 3% for Ultragenyx Pharmaceutical Inc.. Over a 3-year CAGR, SRPT leads at 39. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Sarepta Therapeutics, Inc.

(SRPT) is the more profitable company, earning 12. 4% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 12. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SRPT leads at 11. 5% versus -79. 5% for RARE. At the gross margin level — before operating expenses — RARE leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for RARE: 105.

9% to $51. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Ultragenyx Pharmaceutical Inc.

(RARE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Sarepta Therapeutics, Inc. (SRPT) carries a higher beta of 2. 02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RARE: -60. 0%, SRPT: +30. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.